Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456734 | 0.80 | MAPT (0.38) | MAPTKDM4EHSD17B10 | |
| SCHEMBL7002113 | 0.79 | NPC1 (0.32) | NPC1RAB9ASMN1; SMN2HSD17B10 | |
| SCHEMBL7003724 | 0.79 | PTGS1 (0.30) | — | |
| SCHEMBL14120675 | 0.79 | NPC1 (0.31) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15488276 | 0.79 | CYP3A4 (0.30) | — | |
| SCHEMBL31133971 | 0.76 | MEN1 (0.43) | MAPTKDM4E | |
| SCHEMBL5641626 | 0.76 | KCNH2 (0.35) | — | |
| SCHEMBL30991519 | 0.76 | HCAR3 (0.38) | MAPTKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5741933 | 0.76 | MAPT (0.42) | MAPTNPC1RAB9A | |
| SCHEMBL14120403 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | disclosed |
| EP-1858900-A1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006097691-A1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH2 | DGAT1 3892/4885MAPT 196/4885FAAH 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.